BioHarvest outlines 2026 revenue of $38M-$42M in D2C and $12M-$14M in CDMO activity while targeting 2H 2027 fragrance production (NASDAQ:BHST)


Earnings Call Insights: BioHarvest Sciences (BHST) Q1 2026

Management View

  • “Revenues for the first quarter of 2026 increased 8% year-over-year to $8.5 million from $7.9 million in the same year ago quarter.” (Chief Financial Officer Bar Dichter)
  • “As we announced

Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *